Q-Med launches a pharmaceutical in Sweden

Q-Med hereby announces that a pharmaceutical, Cosmofer® (low molecular iron dextran), has now been approved for sales in Sweden. It is estimated that sales will start towards the end of the year. Q-Med has an agreement with the Danish manufacturer Nebo/Pharmacosmos (www.pharmacosmos.com) concerning sales rights for the preparation on the Swedish market. Cosmofer is given through an infusion in a vein or as an injection in a muscle. What is unique for Cosmofer is that the patient’s total need can be given in a single dose. The product is used for the treatment of serious iron deficiency where treatment with tablets is not tolerated or does not have sufficient effect. The need can be seen above all in people with kidney disease, in cancer patients, in cases of inflammatory intestinal disease, during pregnancy and in connection with surgical procedures when it is desirable to avoid blood transfusions. Q-Med has previous experience of intravenous iron and had sales of a similar preparation up until 1999. WHO estimates that approximately 3 billion people, more than 30% of the world’s population, have anemia, above all due to iron deficiency. In Sweden there are 4 oral iron products, which together have sales of SEK 28.5 million. Only one intravenous product exists today, Venofer, with sales of SEK 26.6 million during 2005. Queries should be addressed to: Erika Kjellberg Eriksson, CFO Tel: + 46 (0) 70-974 90 20 In the US, Q-Med AB´s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden, Tel: 018-474 90 00, Fax: 018-474 90 01 info@q-med.com, www.q-med.com, Org.nr. 556258-6882